Kaijun Li
Hoofd Techniek/Wetenschap/O&O bij China Nuokang Bio-Pharmaceutical, Inc.
Profiel
Kaijun Li is the founder of ClinChoice Medical (TIANJIN) Co., Ltd.
which was founded in 2005.
He was Vice President there in 2007.
He is currently the Chief Scientific Officer at China Nuokang Bio-Pharmaceutical, Inc. since 2007.
In the past, he worked as a Senior Scientist at GenoSpectra, Inc. from 2001 to 2003 and as a Partner at HBM BioMed China Partners Ltd from 2007 to 2009.
Dr. Li received his doctorate degree from Indiana University in 1997.
Actieve functies van Kaijun Li
Bedrijven | Functie | Begin |
---|---|---|
China Nuokang Bio-Pharmaceutical, Inc.
China Nuokang Bio-Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology China Nuokang Bio-Pharmaceutical, Inc. is a biopharmaceutical company focused on the research, development, manufacture, marketing and sales of hematological and cardiovascular products. It currently sells a portfolio of fourteen products, including three principal products: Baquting, its flagship bleeding control product; Aiduo, its cardiovascular stress imaging agent; and Aiwen, its anti-arrhythmic agent. The company has also entered into an exclusive agreement for the marketing and distribution in China of Kaitong, an intravenous injectable lipid emulsion of vasodilator alprostadil for the treatment of peripheral vascular diseases, cardiocerebral microcirculation disorders and post-surgery thrombosis. Its product pipeline includes four product candidates under development that address the growing market and medical needs for hematological, cardiovascular and cerebrovascular disease diagnosis, treatment and prevention. The company was founded on November 1997 and is headquartered in Shenyang, China. | Hoofd Techniek/Wetenschap/O&O | 23-11-2009 |
Eerdere bekende functies van Kaijun Li
Bedrijven | Functie | Einde |
---|---|---|
HBM BioMed China Partners Ltd
HBM BioMed China Partners Ltd Investment ManagersFinance HBM BioMed China Partners Ltd. is a venture capital fund focused on biomedical investments in companies based in China. | Corporate Officer/Principal | 01-01-2009 |
ClinChoice Medical (TIANJIN) Co., Ltd.
ClinChoice Medical (TIANJIN) Co., Ltd. Miscellaneous Commercial ServicesCommercial Services ClinChoice Medical (TIANJIN) Co., Ltd. operates as a contract research organization. It offers consulting, project management, clinical operations, data reporting and laboratory services. The firm also provides good clinical practice compliant clinical research services for multinational clients. The company was founded by Young Wang, Kaijun Li, Dan Zhang and Joanne Jiang Chen in October 2006 and is headquartered in Beijing, the Republic of China. | Oprichter | 01-01-2007 |
GenoSpectra, Inc.
GenoSpectra, Inc. BiotechnologyHealth Technology Genospectra, Inc. was a life science company developing technologies and products for Parallel Quantitative Biology (PQB). Genospectra's PQB initiative was focused on creating novel cell-based assays and tools that enable multiplex measurements of molecular events, such as intracellular pathway analysis, in a quantitative and scalable manner. Genospectra's first product line, the QuantiGene Reagent System was launched in 2003, and was powered by the FDA approved and proprietary branched DNA technology for gene expression analysis in cell-based assays. Genospectra was headquartered in Fremont, CA. | Hoofd Techniek/Wetenschap/O&O | 01-01-2003 |
Opleiding van Kaijun Li
Indiana University | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 4 |
---|---|
China Nuokang Bio-Pharmaceutical, Inc.
China Nuokang Bio-Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology China Nuokang Bio-Pharmaceutical, Inc. is a biopharmaceutical company focused on the research, development, manufacture, marketing and sales of hematological and cardiovascular products. It currently sells a portfolio of fourteen products, including three principal products: Baquting, its flagship bleeding control product; Aiduo, its cardiovascular stress imaging agent; and Aiwen, its anti-arrhythmic agent. The company has also entered into an exclusive agreement for the marketing and distribution in China of Kaitong, an intravenous injectable lipid emulsion of vasodilator alprostadil for the treatment of peripheral vascular diseases, cardiocerebral microcirculation disorders and post-surgery thrombosis. Its product pipeline includes four product candidates under development that address the growing market and medical needs for hematological, cardiovascular and cerebrovascular disease diagnosis, treatment and prevention. The company was founded on November 1997 and is headquartered in Shenyang, China. | Health Technology |
HBM BioMed China Partners Ltd
HBM BioMed China Partners Ltd Investment ManagersFinance HBM BioMed China Partners Ltd. is a venture capital fund focused on biomedical investments in companies based in China. | Finance |
ClinChoice Medical (TIANJIN) Co., Ltd.
ClinChoice Medical (TIANJIN) Co., Ltd. Miscellaneous Commercial ServicesCommercial Services ClinChoice Medical (TIANJIN) Co., Ltd. operates as a contract research organization. It offers consulting, project management, clinical operations, data reporting and laboratory services. The firm also provides good clinical practice compliant clinical research services for multinational clients. The company was founded by Young Wang, Kaijun Li, Dan Zhang and Joanne Jiang Chen in October 2006 and is headquartered in Beijing, the Republic of China. | Commercial Services |
GenoSpectra, Inc.
GenoSpectra, Inc. BiotechnologyHealth Technology Genospectra, Inc. was a life science company developing technologies and products for Parallel Quantitative Biology (PQB). Genospectra's PQB initiative was focused on creating novel cell-based assays and tools that enable multiplex measurements of molecular events, such as intracellular pathway analysis, in a quantitative and scalable manner. Genospectra's first product line, the QuantiGene Reagent System was launched in 2003, and was powered by the FDA approved and proprietary branched DNA technology for gene expression analysis in cell-based assays. Genospectra was headquartered in Fremont, CA. | Health Technology |